TransRadial Education And Therapeutics (TREAT): Shifting the balance of safety and efficacy of antithrombotic agents in percutaneous coronary intervention. A report from the Cardiac Safety Research Consortium

被引：4

作者：

Hess, Connie N. ^{[1
]}

Rao, Sunil V. ^{[1
]}

Kong, David F. ^{[1
]}

Miller, Julie M. ^{[2
]}

Anstrom, Kevin J. ^{[1
]}

Bertrand, Olivier F. ^{[3
]}

Collet, Jean-Philippe ^{[4
]}

Effron, Mark B. ^{[5
]}

Eloff, Benjamin C. ^{[6
]}

Fadiran, Emmanuel O. ^{[6
]}

Farb, Andrew ^{[6
]}

Gilchrist, Ian C. ^{[7
]}

Holmes, David R. ^{[8
]}

Jacobs, Alice K. ^{[9
]}

Kaul, Prashant ^{[10
]}

Newby, L. Kristin ^{[1
]}

Rutledge, David R. ^{[11
]}

Tavris, Dale R. ^{[6
]}

Tsai, Thomas T. ^{[12
]}

White, Roseann M. ^{[11
]}

Peterson, Eric D. ^{[1
]}

Krucoff, Mitchell W. ^{[1
]}

机构：

[1] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA

[2] Johns Hopkins Univ, Baltimore, MD USA

[3] Quebec Heart Lung Inst, Quebec City, PQ, Canada

[4] Inst Cardiol, Paris, France

[5] Lilly USA LLC, Indianapolis, IN USA

[6] US FDA, Silver Spring, MD USA

[7] Penn State Heart & Vasc Inst, Hershey, PA USA

[8] Mayo Clin, Rochester, MN USA

[9] Boston Med Ctr, Boston, MA USA

[10] Univ N Carolina, Chapel Hill, NC USA

[11] Abbott Vasc, San Francisco, CA USA

[12] Denver VA Med Ctr, Denver, CO USA

来源：

AMERICAN HEART JOURNAL | 2013年 / 165卷 / 03期

关键词：

CLINICAL-OUTCOMES; FEMORAL APPROACH; VASCULAR COMPLICATIONS; ANTIPLATELET THERAPY; GENDER-DIFFERENCES; BLOOD-TRANSFUSION; ADVERSE OUTCOMES; ACCESS; IMPACT; ANGIOGRAPHY;

D O I：

10.1016/j.ahj.2012.09.008

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Percutaneous coronary intervention (PCI) is an integral part of the treatment of coronary artery disease. The most common complication of PCI, bleeding, typically occurs at the vascular access site and is associated with short-term and long-term morbidity and mortality. Periprocedural bleeding also represents the primary safety concern of concomitant antithrombotic therapies essential for PCI success. Use of radial access for PCI reduces procedural bleeding and hence may change the risk profile and net clinical benefit of these drugs. This new drug-device safety interaction creates opportunities to advance the safe and effective use of antithrombotic agents during PCI. In June 2010 and March 2011, leaders from government, academia, professional societies, device manufacturing, and pharmaceutical industries convened for 2 think tank meetings. Titled TREAT I and II, these forums examined approaches to improve the overall safety of PCI by optimizing strategies for antithrombotic drug use and radial artery access. This article summarizes the content and proceedings of these sessions. (Am Heart J 2013;165:344-353.e1.)

引用

页码：344 / +

页数：11

共 48 条

[11] Association of the arterial access site at angioplasty with transfusion and mortality: the MORTAL study (Mortality benefit Of Reduced Transfusion after percutaneous coronary intervention via the Arm or Leg) [J].

Chase, A. J. ;

Fretz, E. B. ;

Warburton, W. P. ;

Klinke, W. P. ;

Carere, R. G. ;

Pi, D. ;

Berry, B. ;

Hilton, J. D. .

HEART, 2008, 94 (08) :1019-1025

[12] Effect of transradial access on quality of life and cost of cardiac catheterization: A randomized comparison [J].

Cooper, CJ ;

El-Shiekh, RA ;

Cohen, DJ ;

Blaesing, L ;

Burket, MW ;

Basu, A ;

Moore, JA .

AMERICAN HEART JOURNAL, 1999, 138 (03) :430-436

[13] Bleeding, Blood Transfusion, and Increased Mortality After Percutaneous Coronary Intervention Implications for Contemporary Practice [J].

Doyle, Brendan J. ;

Rihal, Charanjit S. ;

Gastineau, Dennis A. ;

Holmes, David R., Jr. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 53 (22) :2019-2027

[14] Gender differences in adverse outcomes after contemporary percutaneous coronary intervention: An analysis from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) percutaneous coronary intervention registry [J].

Duvernoy, Claire S. ;

Smith, Dean E. ;

Manohar, Prerana ;

Schaefer, Ann ;

Kline-Rogers, Eva ;

Share, David ;

McNamara, Richard ;

Gurm, Hitinder S. ;

Moscucci, Mauro .

AMERICAN HEART JOURNAL, 2010, 159 (04) :677-U210

[15]

Eggebrecht Holger, 2004, J Invasive Cardiol, V16, P247

[16]

FDA, 2004, INN STAGN CHALL OPP

[17]

Fung M, 2001, DRUG INF J, V35, P293, DOI 10.1177/009286150103500134

[18] Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial [J].

Jolly, Sanjit S. ;

Yusuf, Salim ;

Cairns, John ;

Niemela, Kari ;

Xavier, Denis ;

Widimsky, Petr ;

Budaj, Andrzej ;

Niemela, Matti ;

Valentin, Vicent ;

Lewis, Basil S. ;

Avezum, Alvaro ;

Steg, Philippe Gabriel ;

Rao, Sunil V. ;

Gao, Peggy ;

Afzal, Rizwan ;

Joyner, Campbell D. ;

Chrolavicius, Susan ;

Mehta, Shamir R. .

LANCET, 2011, 377 (9775) :1409-1420

[19] Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events: A systematic review and meta-analysis of randomized trials [J].

Jolly, Sanjit S. ;

Amlani, Shoaib ;

Hamon, Martial ;

Yusuf, Salim ;

Mehta, Shamir R. .

AMERICAN HEART JOURNAL, 2009, 157 (01) :132-140

[20] Meta-Analysis of Ten Trials on the Effectiveness of the Radial Versus the Femoral Approach in Primary Percutaneous Coronary Intervention [J].

Joyal, Dominique ;

Bertrand, Olivier F. ;

Rinfret, Stephane ;

Shimony, Avi ;

Eisenberg, Mark J. .

AMERICAN JOURNAL OF CARDIOLOGY, 2012, 109 (06) :813-818

← 1 2 3 4 5 →